Insight
Evandro de Azambuja
Evandro de Azambuja/LinkedIn

Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer

Evandro de Azambuja, President of the Belgian Society of Medical Oncology (BSMO) for 2023-2026, shared a post on LinkedIn:

“Our group just reflected on this important issue on managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: An Emerging Challenge.”

Title: Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge

 Authors: R. Gerosa, G. Gentile, L. Arecco, C. Dauccia, S. Nannini, S. Lobo-Martins, E. Agostinetto, M. Lambertini, A. Santoro, P. Aftimos, M. Piccart-Gebhart, E. de Azambuja

Read the Full Article.

Evandro de Azambuja: Managing Relapses During or After Adjuvant CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer

More from Evandro de Azambuja on OncoDaily.

A. Santoro C. Dauccia cancer E. Agostinetto E. de Azambuja Evandro de Azambuja G. Gentile L. Arecco M. Lambertini M. Piccart-Gebhart OncoDaily Oncology P. Aftimos R. Gerosa S. Lobo-Martins S. Nannini